October 30, 2020
For kidney transplant patients with gout, the use of anti-inflammatory drugs and urate-lowering therapies typically used to prevent flares and slow the progression disease, are associated with the risk of adverse events. In this interview, Dr. Abdul Abdellatif describes a clinical trial that shows pegloticase may be suitable for transplant patients with gout.
October 29, 2020
Anti-inflammatory and immunosuppressive agents are the two primary classes of drugs used to treat lupus nephritis. Now, a new study shows that the addition of the monoclonal antibody belimumab to standard therapy may make a meaningful difference in this hard-to-treat patient population.
October 29, 2020
Although mortality rates for kidney transplant recipients with COVID-19 are known to be high, end stage kidney disease patients with COVID-19 appear to have a higher risk of mortality than patients with new kidneys.
October 28, 2020
A possible new treatment for advanced lupus nephritis passes a phase two trial, according to a study presented at Kidney Week, the annual meeting of the American Society for Nephrology. The treatment, a CD20 antagonist called obinutuzumab, led to improvements in 41 percent of patients with lupus nephritis—a condition that affects one in 60 people with systemic lupus.
October 27, 2020
From COVID-19 presentations to emerging new therapies for chronic kidney disease, Dr. Bradley Marder, medical director of nephrology with Horizon Therapeutics, offers his take on the most memorable moments from the American Society for Nephrology/Kidney Week annual meeting which wrapped this week.
October 23, 2020
The gout treatment allopurinol doesn't appear to slow the progression of chronic kidney disease in patients with moderate to severe loss of kidney function, shows a study presented yesterday at the American Society of Nephrology Kidney Week annual meeting.
October 23, 2020
In today's featured video, we talk with Dr. Brad Marder, medical director at Horizon Therapeutics, who shares with us the details of three studies presented at the American Society of Nephrology annual meeting which is taking place this week online. The studies highlight the preliminary results of clinical trials for new gout treatments. In this interview, he explains why this research is important.
October 23, 2020
In this week's news roundup from Rheumatology Network, we highlight studies presented at the American Society of Nephrology Kidney Week annual meeting taking place this week, including a study that shows the gout treatment allopurinol doesn’t slow kidney disease and another that estimates the annual cost of lupus nephritis at $50,000. These and other headlines are included in this week's news roundup.
October 23, 2020
Treatments for lupus nephritis can cost patients over $50,000 a year, according to a study presented yesterday at the American Society of Nephrology Kidney Week annual meeting.